1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
OptiBiotix Health Plc

OptiBiotix Health Plc

OPTI.L
OptiBiotix Health PlcGB flagLondon Stock Exchange
6.30
GBp
-0.05
- -
6.51MMarket Cap
OptiBiotix Health Plc
OPTI.L
(London Stock Exchange)

Recent

price

6.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2012
2014
2015
2016
2017
2018
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.02
0.03
0.01
0.01
0.01
0.01
Revenue per Share
-4.03
-2.01
-4.53
-22.01
-0.03
-0.02
-0.02
0.02
-0.02
0.07
0.07
0.03
-0.02
-0.02
-0.04
Basic EPS, GAAP
-3.4
-8.18
-5.29
-6.93
-0.03
-0.01
-0.02
-0.02
-0.02
-0.01
-0.02
-0.01
-0.02
-0.02
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
100.44
98.55
93.9
4.34
-0.03
-0.03
-0.04
-0.02
0.04
0.08
0.15
0.06
0.04
0.03
-0.01
Book Value per Share
103.84
101.95
97.29
7.14
0.09
0.02
0.04
0.07
0.06
0.1
0.18
0.11
0.08
0.07
0.05
Tangible Book Value per Share
- -
- -
- -
- -
27
73
78
79
82
87
88
88
90
98
101
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
2
2
- -
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-5,046.99
-526.11
-1,113.08
-291.45
-72.96
-61.68
-2,301.75
-263.35
-260.46
-268.61
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-4
-1
-1
-1
2
-2
6
6
3
-2
-2
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-4,541.24
-450.46
998.28
-373.19
380.89
282.92
566.08
-316.61
-207.47
-333.62
Profit Margin (%)
1
1
1
1
3
2
3
1
2
1
3
2
1
1
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
- -
- -
LT Debt
1
1
1
2
5
4
5
7
7
12
18
11
9
8
6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-2.02
-4.71
-522.89
- -
- -
- -
- -
- -
114.47
62.93
27.84
-44.57
-58.36
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.62%
-7.17%
-25.2%
Free Cash Flow
12.55%
9.13%
0.11%
Net Income, GAAP
-91.61%
-25.11%
115.51%
Sales/Revenue/Turnover
- -
15.19%
34.02%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.02
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
- -
- -
-0.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Open Orphan Plc (ORPH.IR)
Foundation Medicine, Inc. (FMI)
TME Pharma N.V. (ALTME.PA)
Accustem Sciences Inc. (ACUT)
Shanghai ZJ Bio-Tech Co., Ltd. (688317.SS)
CorMedix Inc. (CRMD)
Business
OptiBiotix Health Plc develops microbiome modulators for use in food ingredients, supplements and active pharmaceutical compounds targeting chronic lifestyle diseases such as obesity, hypercholesterolemia, cardiovascular disease and diabetes; its core branded products include SlimBiome for appetite suppression and weight management, LeanBiome for sports nutrition applications, WellBiome for gut health and microbiome enhancement, SweetBiotix as a natural high-intensity sweetener and healthy sugar substitute, and additional microbiome modulators like LPGOS. The company, founded in 2012 and headquartered at Innovation Centre, Innovation Way, Heslington, York YO10 5DG, England, operates globally with sales channels in Europe, North America, Asia including India and China, Australia and ecommerce platforms such as Amazon; it maintains subsidiaries including OptiBiotix Health India and holds stakes in related entities SkinBioTherapeutics Plc and ProBiotix Health Plc. Recent developments encompass partnerships with Morepen Laboratories for SlimBiome-based LightLife weight management products launched in India in December 2024 with repeat orders in 2025, Daily Nouri for FeelFull prebiotic lemonade in the USA launched February 2025, Brenntag as Australian distributor with a six metric tonne order in Q2 2025, MuscleTech for LeanBiome in Nitro Tech Ripped, Tata Chemicals for LPGOS, and DSM-Firmenich for SweetBiotix; the company reported 35% revenue growth to £870k for 2024 with orders up 56% to £1,004k, ecommerce sales doubling to £387k, a £750k placing in May 2025, appointment of David Blain as Finance Director in January 2025, and ongoing US launches including with a NASDAQ-listed partner and a major weight management brand targeting Walmart.